Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Settings

Settings

Goto Application

1. WO2022008418 - SPECIFIC BINDING MOLECULES

Publication Number WO/2022/008418
Publication Date 13.01.2022
International Application No. PCT/EP2021/068471
International Filing Date 05.07.2021
IPC
C07K 16/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12against material from bacteria
C07K 14/74 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
74Major histocompatibility complex (MHC)
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 14/725 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Applicants
  • IMMUNOCORE LIMITED [GB]/[GB]
Inventors
  • LEONARD, Sarah
  • PATERSON, Rachel
  • DE SOUZA, Victoria Arena
  • DEMBEK, Marcin
Agents
  • KILBURN & STRODE LLP
Priority Data
2010329.706.07.2020GB
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SPECIFIC BINDING MOLECULES
(FR) MOLÉCULES DE LIAISON SPÉCIFIQUES
Abstract
(EN) The present invention relates to specific binding molecules which bind to the HLA-E restricted peptide RLPAKAPLL (SEQ ID NO: 1) derived from Mycobacterium tuberculosis enoyl-ACP reductase. Said specific binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of infectious disease.
(FR) La présente invention concerne des molécules de liaison spécifiques qui se lient au peptide restreint HLA-E RLPAKAPLL (SEQ ID NO : 1) dérivé de l'énoyl-ACP réductase de mycobacterium tuberculosis. Lesdites molécules de liaison spécifiques peuvent comprendre des séquences CDR enchâssées au sein d'une séquence de charpente. Les CDR et les séquences de charpente peuvent correspondre à un domaine variable de récepteur de cellules T (TCR) et peuvent en outre comprendre des mutations non naturelles concernant un domaine variable TCR d'origine naturelle. Les molécules de liaison spécifiques selon l'invention sont particulièrement appropriées pour une utilisation comme nouveaux réactifs immunothérapeutiques destinés au traitement de maladies infectieuses.
Latest bibliographic data on file with the International Bureau